Furthermore, Dulal et al. [73] also showed that a combination anti-PD-1 therapy combined with MEK inhibition (MEK inhibits MAPK pathway) produced lasting tumor regression in CT26-innoculated BALB/c mice. The gene discussed is MAP2K7; the disease is neoplasm.